<DOC>
	<DOCNO>NCT00283114</DOCNO>
	<brief_summary>Phase 1a open-label , multi-dose , single-arm , dose-escalation study define toxicity profile , pharmacokinetics , antitumor activity SGN-33 patient myelodysplastic syndrome ( MDS ) , acute myelogenous leukemia ( AML ) , CD33+ myeloproliferative disease . Phase 1b include patient AML MDS treat high tolerate dose phase 1a .</brief_summary>
	<brief_title>A Safety Study Lintuzumab Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients must diagnosis MDS AML . 2 . Patients must ECOG performance status ≤ 2 life expectancy &gt; 3 month . 1 . Patients receive prior therapy gemtuzumab ozogamicin ( Mylotarg® ) antiCD33 monoclonal antibody treatment . 2 . Patients prior allogeneic transplant . 3 . Patients know leptomeningeal CNS involvement leukemia . Patients onset CNS symptom within past 12 month also exclude . 4 . Patients receive chemotherapy within last four week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Lintuzumab</keyword>
	<keyword>Antigens , CD33</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Leukemia , Myeloid , Acute</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Leukemia</keyword>
</DOC>